Solid Biosciences (SLDB) Change in Account Payables (2017 - 2026)

Solid Biosciences has reported Change in Account Payables for 10 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Change in Account Payables rose 403.47% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $767000.0 (down 76.49% YoY) and the FY2025 annual result came in at -$1.1 million, down 149.57% from the prior year.
• Change in Account Payables advanced to $2.3 million in Q1 2026 per SLDB's latest filing, from -$5.3 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.7 million in Q3 2025 and troughed at -$5.9 million in Q4 2022.
• A 5-year average of -$151588.2 and a median of $287000.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables tumbled 1136.14% in 2022, then surged 3766.2% in 2023.
• Over 5 years, Change in Account Payables stood at -$5.9 million in 2022, then jumped by 102.27% to $134000.0 in 2023, then soared by 508.21% to $815000.0 in 2024, then plunged by 745.03% to -$5.3 million in 2025, then soared by 144.15% to $2.3 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $2.3 million, -$5.3 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.